Ccr5 deficiency abrogated the IL-32–mediated CD8+ T cell infiltration and its therapeutic effect, i.e., tumor growth reduction, highlighting the induction of T cell–recruiting chemokines as a key effector mechanism of IL-32 in tumor immunity. This evidence concerns the gene CCR5 and neoplasm.